Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study
Year: 2023
Type: article
Study design: Study Protocol
Abstract: A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative's TransBioLine consortium comprising academic and industry partners is developing a prospective repository of deeply phenotyped cases and controls with biological samples during liver injury progression to facilitate biomarker discovery, evaluation, validation and qualification.In a nested case-control design, patients who meet one of these criteria, alanine transaminase (ALT) ≥ 5 × the upper limit of normal (ULN), alkaline phosphatase ≥ 2 × ULN or ALT ≥ 3 ULN with total bilirubin > 2 × ULN, are enrolled. After completed clinical investigations, Roussel Uclaf Causality Assessment and expert panel review are used to adjudicate episodes as DILI or alternative liver diseases (acute non-DILI controls). Two blood samples are taken: at recruitment and follow-up. Sample size is as follows: 300 cases of DILI and 130 acute non-DILI controls. Additional cross-sectional cohorts (1 visit) are as follows: Healthy volunteers (n = 120), controls with chronic alcohol-related or non-alcoholic fatty liver disease (n = 100 each) and patients with psoriasis or rheumatoid arthritis (n = 100, 50 treated with methotrexate) are enrolled. Candidate biomarkers prioritised for evaluation include osteopontin, glutamate dehydrogenase, cytokeratin-18 (full length and caspase cleaved), macrophage-colony-stimulating factor 1 receptor and high mobility group protein B1 as well as bile acids, sphingolipids and microRNAs. The TransBioLine project is enabling biomarker discovery and validation that could improve detection, diagnostic accuracy and prognostication of DILI in premarketing clinical trials and for clinical healthcare application.
Authors: Jane I. Grove, Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade, Sabine Weber, Alexander Gerbes, Einar S. Bjornsson, Guido Stirnimann, Ann K. Daly, Matthias Hackl, Kseniya Khamina-Kotisch, Jose J. G. Marin, Maria J. Monte, Sara A. Paciga, Melanie Lingaya, Shiva S. Forootan, Christopher E. P. Goldring, Oliver Poetz, Rudolf Lombaard, Alexandra Stege, Helgi K. Bjorrnsson, Mercedes Robles-Diaz, Dingzhou Li, Thi Dong Binh Tran, Shashi K. Ramaiah, Sophia L. Samodelov, Gerd A. Kullak-Ublick, Guruprasad P. Aithal
Institutions: Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham Biomedical Research Centre, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Andalusian Centre for Nanomedicine and Biotechnology, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, LMU Klinikum, Ludwig-Maximilians-Universität München, University of Iceland, National University Hospital of Iceland, University of Bern, University Hospital of Bern, Newcastle University, TAmiRNA (Austria), Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Pfizer (United States), University of Liverpool, Signatope GmbH (Germany), Charité – Universitätsmedizin Berlin, Sahlgrenska University Hospital, University of Zurich, University Hospital Zurich, Novartis (Switzerland)
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Keywords: drug-induced liver injury, safety biomarkers, nested case-control study, biomarker discovery, osteopontin, glutamate dehydrogenase, cytokeratin 18, high mobility group protein B1, bile acids, sphingolipids, microRNA, methotrexate, non-alcoholic fatty liver disease, alcoholic liver disease, psoriasis, rheumatoid arthritis, liver injury progression, biomarker validation
Open Access status: gold
Estimated APC paid: $2,490
Awards: G1466063397, Centre for Drug Safety Science (CDSS), NIHR Senior Investigator Award, Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease, G3872850769, G4093197094, G434337789, G5968716317, G7223870706
OpenAlex ID: W4386617699
